Obesity clinical trial intelligence

Project Diabetes: Weight Gain Prevention in Hispanic Girls (GEMAS Study)

Project Diabetes: Weight Gain Prevention in Hispanic Girls (GEMAS Study) is a NA clinical asset sponsored by Vanderbilt University in Obesity, Diet, Exercise, Behavioral Research. SEO and diligence focus: Active intervention, Alternative Intervention, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Obesity

A Randomized Study to Investigate the Effect of Low-calorie Diets With Different Macronutrient Composition and Macronutrient Distribution in Shift Workers With Prediabetes or Type 2 Diabetes and Overweight or Obesity.

A Randomized Study to Investigate the Effect of Low-calorie Diets With Different Macronutrient Composition and Macronutrient Distribution in Shift Workers With Prediabetes or Type 2 Diabetes and Overweight or Obesity. is a NA clinical asset sponsored by Universidad de Zaragoza in Type 2 Diabetes, Overweight or Obesity, PreDiabetes. SEO and diligence focus: Diet, Diet, Diet, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Overweight or Obesity

Mindfulness-Based Nutrition Group Therapy as an Adjunct to GLP-1 Treatment of Obesity

Mindfulness-Based Nutrition Group Therapy as an Adjunct to GLP-1 Treatment of Obesity is a NA clinical asset sponsored by Bern University of Applied Sciences in Obesity & Overweight, Emotional Eating Behaviour, Mindful Eating Intervention. SEO and diligence focus: Mindfulness-based nutritional group therapy (MBNGT), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Obesity & Overweight

Yoga Improves Aerobic Fitness, Glycemia and Mood State and Reduces Abdominal Obesity in Overweight Women: The PRISE Study

Yoga Improves Aerobic Fitness, Glycemia and Mood State and Reduces Abdominal Obesity in Overweight Women: The PRISE Study is a NA clinical asset sponsored by Skidmore College in Obesity, Insulin Resistance. SEO and diligence focus: Protein whole foods, Protein Resistance Exercise Training, Protein Stretching/Yoga Training, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Obesity

Preoperative Predictors of Weight Loss and Improved Metabolic Health After Bariatric Surgery

Preoperative Predictors of Weight Loss and Improved Metabolic Health After Bariatric Surgery is a registry-stage clinical asset sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) in Obesity, Morbid, Insulin Sensitivity, Bariatric Surgery Candidate, Feeding Behavior. SEO and diligence focus: mRNA, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Obesity, Morbid

A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes

A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes is a PHASE2 clinical asset sponsored by Hanmi Pharmaceutical Company Limited in Obesity. SEO and diligence focus: HM11260C, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Obesity

The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Manifestation of Starvation Ketosis and Ketoacidosis in Patients With Nonalcoholic Steatohepatitis

The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Manifestation of Starvation Ketosis and Ketoacidosis in Patients With Nonalcoholic Steatohepatitis is a NA clinical asset sponsored by The Society of Bariatric and Metabolic Surgeons of Kazakhstan in Obesity, Morbid, NASH, Ketosis, Keto Acidosis, Carbohydrate Metabolism Disorder. SEO and diligence focus: Carbohydrate Restriction after a Gastric Bypass, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Obesity, Morbid

Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients

Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients is a PHASE3 clinical asset sponsored by Lindner Center of HOPE in Binge Eating Disorder Associated With Obesity. SEO and diligence focus: Zonegran, sugar pill, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Binge Eating Disorder Associated With Obesity

Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)

Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2) is a PHASE3 clinical asset sponsored by Eli Lilly and Company in Type 2 Diabetes, Overweight, Obesity. SEO and diligence focus: Tirzepatide, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Overweight

Behavioral Family Systems Therapy for Teens With Type 2 Diabetes: A Pilot

Behavioral Family Systems Therapy for Teens With Type 2 Diabetes: A Pilot is a NA clinical asset sponsored by Nemours Children's Clinic in Diabetes Mellitus, Type 2, Childhood Obesity. SEO and diligence focus: BFST for Teens with Type 2 Diabetes, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Childhood Obesity

A Controlled Study Aiming to Increase Physical Activity and Decrease Risk Bio-markers in Sedentary 8 Year Old Swedish Children Via Physical Activity and Fish Liver Oil Supplementation

A Controlled Study Aiming to Increase Physical Activity and Decrease Risk Bio-markers in Sedentary 8 Year Old Swedish Children Via Physical Activity and Fish Liver Oil Supplementation is a NA clinical asset sponsored by Karolinska Institutet in Cardiovascular Risk Factors, Metabolic Risk Factors, Sedentary Lifestyle, Overweight. SEO and diligence focus: Motivational Interviewing, Physical activity, Supplementation with fish liver oli capsules, Placebo oil capsules, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Overweight

Safety and Feasibility of the ENDOPLY System in Humans: a Pilot Study

Safety and Feasibility of the ENDOPLY System in Humans: a Pilot Study is a NA clinical asset sponsored by ENDOPLY in Obesity. SEO and diligence focus: ENDOPLY System, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Obesity

Impact of Time-Restricted Eating on Metabolic and Neuroendocrine Homeostasis, Inflammation and Oxidative Stress in Patients With Metabolic Syndrome: the TREMNIOS Pilot Clinical Trial

Impact of Time-Restricted Eating on Metabolic and Neuroendocrine Homeostasis, Inflammation and Oxidative Stress in Patients With Metabolic Syndrome: the TREMNIOS Pilot Clinical Trial is a NA clinical asset sponsored by Nicolaus Copernicus University in Metabolic Syndrome, Overweight or Obesity, PreDiabetes, Weight Loss, Quality of Life. SEO and diligence focus: Time-Restricted Eating, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Overweight or Obesity

Investigation of Inflammation Induced by Obstructive Sleep Apnea: Effects of Continuous Positive Airway Pressure (CPAP), Massive Weight Loss and the Bioactive Compound Resveratrol

The study, sponsored by the University of Aarhus, aimed to investigate the metabolic changes induced by OSA and the effects of massive weight loss post-bariatric surgery on inflammation and insulin sensitivity. Given the high prevalence of OSA among obese individuals and its association with significant comorbidities, the findings could have substantial implications for the development of therapeutic strategies targeting inflammation and metabolic disorders. The market for obesity-related treatments, including bariatric surgery and associated metabolic therapies, is considerable, with ongoing demand for effective interventions. The discontinuation of the resveratrol and CPAP components may limit the study's broader applicability but allows for a focused analysis of weight loss effects, which is a critical area of interest in obesity management.

"SFB 1052/3 - Mechanismen Der Adipositas, Projekt A1: Veränderung Der Neurobiologischen Grundlagen Von Ess-Entscheidungen Bei Adipositas" Engl. "CRC 1052/3 - Obesity Mechanisms, Project A1: Targeting Neurobehavioral Determinants of Obesity"

"SFB 1052/3 - Mechanismen Der Adipositas, Projekt A1: Veränderung Der Neurobiologischen Grundlagen Von Ess-Entscheidungen Bei Adipositas" Engl. "CRC 1052/3 - Obesity Mechanisms, Project A1: Targeting Neurobehavioral Determinants of Obesity" is a NA clinical asset sponsored by Max Planck Institute for Human Cognitive and Brain Sciences in Overweight and Obesity. SEO and diligence focus: Inulin, Lifestyle intervention, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Overweight and Obesity

Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)

The REVISE-Diabesity trial investigates the efficacy of the Endobarrier device in conjunction with Liraglutide for treating obesity and type 2 diabetes in patients unresponsive to conventional therapies. Given the rising prevalence of obesity and T2DM, this study addresses a significant unmet medical need, potentially positioning the Endobarrier as a viable non-surgical alternative to bariatric surgery. The outcomes could enhance market competitiveness against existing GLP-1 receptor agonists and other obesity treatments, while also informing future product development strategies. Stakeholders should consider the implications of successful results on market access, reimbursement strategies, and potential partnerships for commercialization.

Matched by conditions: Obesity

Effect of Soy Protein and Polydextrose on Food Intake in Young Chinese Adult Males

The study conducted by the Singapore Institute of Food and Biotechnology Innovation explores the effects of soy protein and polydextrose on food intake and satiety in a specific demographic (young Chinese males). Given the rising global obesity rates, the findings could have significant implications for weight management products and dietary supplements. The potential market for functional foods that enhance satiety is substantial, particularly in Asia, where soy products are culturally integrated. Competitively, this research may position the sponsor as a leader in the development of innovative dietary solutions targeting obesity and metabolic health. Diligence should focus on the commercial viability of the findings and potential partnerships with food manufacturers or health-focused brands.

Matched by conditions: Obesity

Inflammatory Mediators in Obese Adolescents With Insulin Resistance Following Metformin Treatment: Controlled Randomized Clinical Trial

This clinical trial, sponsored by Hospital Regional de Alta Especialidad del Bajio, investigates the effects of metformin on inflammatory mediators in obese adolescents with insulin resistance. The increasing prevalence of obesity and associated metabolic disorders in pediatric populations presents a significant market opportunity for treatments targeting insulin resistance and inflammation. Metformin, a well-established drug, is already used for diabetes management, which may facilitate its acceptance in this new indication. The competitive landscape includes lifestyle interventions and other pharmacological agents, but metformin's established safety profile and efficacy in reducing insulin resistance may provide a competitive edge. Diligence should focus on regulatory pathways and potential market access challenges in pediatric populations.

Matched by conditions: Obesity

Energy Balance Interventions for Colorectal Cancer Prevention

The study, sponsored by Vanderbilt University, investigates the impact of dietary energy restriction and physical activity on colorectal cancer prevention in at-risk populations. With rising obesity rates and increasing awareness of cancer prevention strategies, this trial addresses a significant market need. The findings could inform future dietary guidelines and intervention programs, potentially leading to partnerships with health organizations and dietary supplement companies. The competitive landscape includes other lifestyle intervention studies targeting cancer prevention, necessitating a thorough diligence process to assess market positioning and potential collaborations.

Matched by conditions: Obesity

A Proof-of-Concept Study Examining the Addition of Yoga to a Behavioral Weight Loss Intervention on Energy Balance and Health-Related Outcomes

The study, sponsored by the University of Colorado, Denver, investigates the integration of yoga into a behavioral weight loss program for adults with obesity. Given the rising prevalence of obesity and related metabolic disorders, this research addresses a significant market need for innovative weight management strategies. If successful, the findings could lead to the development of new behavioral health programs that incorporate yoga, potentially enhancing patient adherence and outcomes. The competitive landscape includes traditional weight loss programs and emerging holistic health interventions. Diligence should focus on the feasibility of scaling such interventions and the potential for partnerships with wellness organizations or healthcare providers.

Matched by conditions: Obesity

Mechanistic Studies in Human Subcutaneous Adipose Tissue

The AMIGROS study, sponsored by Vastra Gotaland Region, aims to elucidate the role of galectin-1 in obesity and type 2 diabetes by comparing obese insulin-sensitive (Ob-IS) and insulin-resistant (Ob-IR) subjects with lean controls. Given the increasing prevalence of obesity and type 2 diabetes globally, understanding the mechanistic pathways involving galectin-1 could lead to novel therapeutic targets. The findings may have significant implications for drug development in metabolic disorders, particularly in identifying biomarkers for early intervention and personalized treatment strategies. The study's observational nature may limit immediate commercial applications but could pave the way for future clinical trials targeting galectin-1 modulation. The competitive landscape includes existing diabetes and obesity therapies, necessitating a robust differentiation strategy based on the mechanistic insights gained from this research.

Matched by conditions: Obesity

A Proof-of-Concept, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of Oral NG101 in the Treatment of Side Effects in Healthy Adult Participants Administered a Single Subcutaneous Dose of a Glucagon-Like Peptide 1 Agonist

Neurogastrx, Inc.'s NG101 is positioned to address a significant unmet need in the management of gastrointestinal side effects related to GLP-1 agonists, which are increasingly prescribed for obesity and diabetes management. The trial's completion indicates readiness for further development, potentially enhancing the therapeutic profile of GLP-1 therapies. If successful, NG101 could capture a share of the growing obesity treatment market, which is projected to expand significantly in the coming years. Competitive analysis suggests that while several GLP-1 agonists are already established, a complementary treatment for their side effects could differentiate Neurogastrx in a crowded landscape. Diligence should focus on regulatory pathways and potential partnerships with GLP-1 agonist manufacturers.

A Randomised, Placebo-controlled, Double-blind, Incomplete Cross-over Design Trial to Evaluate the Effects of Liraglutide on Gastric Emptying, Energy Expenditure and Appetite, and to Evaluate Liraglutide Pharmacokinetics in Non-diabetic Obese Subjects

Liraglutide, a GLP-1 receptor agonist, is being evaluated for its effects on gastric emptying, energy expenditure, and appetite regulation in non-diabetic obese subjects. Given the rising prevalence of obesity and related metabolic disorders, this trial positions Novo Nordisk to potentially expand liraglutide's indications beyond diabetes management into obesity treatment. The competitive landscape includes other GLP-1 receptor agonists and weight management therapies, necessitating a robust differentiation strategy. Successful outcomes could enhance market share in the obesity treatment segment, which is projected to grow significantly. Diligence should focus on the trial's efficacy and safety data, as well as the regulatory landscape for obesity treatments.

Matched by conditions: Obesity

The Effects of a Daily Intake of Protein From Cod Fillet and Cod Residual Material for 8 Weeks on Serum Lipids and Fatty Acids, Glucose Regulation and Inflammation Markers in Overweight or Obese Adults: A Randomized Controlled Trial.

The study investigates the health effects of cod protein, both from fillet and residual materials, on overweight or obese adults. Given the rising prevalence of obesity and related metabolic disorders, this research could position cod protein as a functional food ingredient with potential applications in dietary supplements and food products targeting cardiovascular health and glucose regulation. The findings may open avenues for partnerships with food manufacturers and health supplement companies, particularly in markets focused on obesity management and chronic disease prevention. The competitive landscape includes other protein sources and dietary interventions, necessitating a clear differentiation based on efficacy and health benefits derived from cod protein.

Matched by conditions: Overweight and Obesity

Determining the Optimal Reduction in Sedentary Behaviour to Reduce Glycemic Variability and Maintain Cognition: a Randomized Control Trial

The DURATION Study, sponsored by Western University, aimed to explore the impact of reducing sedentary behavior on glycemic variability and cognitive function in older adults with mild cognitive impairment and diabetes. Although the trial has been withdrawn due to the principal investigator's change in role, the underlying hypothesis addresses a significant market need for interventions targeting cognitive decline and diabetes management in aging populations. The findings could have implications for lifestyle modification programs and digital health solutions aimed at improving health outcomes in older adults, a demographic that is rapidly growing and increasingly burdened by chronic diseases. The competitive landscape includes various lifestyle intervention programs and digital therapeutics focused on physical activity and cognitive health, indicating a need for differentiation in approach and technology integration.

Matched by conditions: Overweight and Obesity

Phase 3: Effect of Diet, Physical Activity and Insulin Sensitizer Metformin on Obesity and Associated Risks in Children and Adolescents.

The Phase 3 trial conducted by the Lithuanian University of Health Sciences investigates the efficacy of Metformin in conjunction with lifestyle interventions (diet and physical activity) for treating obesity in children and adolescents. Given the rising prevalence of obesity and associated metabolic disorders in pediatric populations, successful outcomes could position Metformin as a first-line treatment option in this demographic, potentially expanding its market beyond adult diabetes management. The competitive landscape includes other anti-obesity medications and lifestyle intervention programs, necessitating a thorough analysis of efficacy, safety, and long-term outcomes to ensure a favorable market entry. Diligence should focus on regulatory pathways and reimbursement strategies for pediatric use.

Matched by conditions: Obesity

Take Active Breaks From Sitting (TABS): Reducing Sedentary Time in Older Adults

The TABS trial, sponsored by Kaiser Permanente, targets the growing concern of sedentary lifestyles among older adults, particularly those with obesity. With over one-third of American adults aged 60+ classified as obese, this intervention addresses a significant public health issue. The findings could inform future health programs and interventions, potentially leading to partnerships with healthcare providers and insurers focused on preventive care. The market for obesity management and lifestyle interventions is expanding, and successful outcomes may position Kaiser Permanente as a leader in this niche, enhancing its reputation and service offerings. Competitive implications include the potential for similar programs from other healthcare organizations, necessitating a focus on unique value propositions and outcomes to maintain a competitive edge.

Matched by conditions: Obesity

Pilot Study Testing Professional, Peer, and Mentor Health Coaches for Weight Loss

This pilot study, sponsored by The Miriam Hospital, explores the feasibility and preliminary efficacy of different types of health coaching for weight loss in adults aged 40-60. The market for obesity management is significant, with increasing demand for effective weight loss solutions. The competitive landscape includes various behavioral intervention programs, but this study's unique approach of comparing peer, mentor, and professional coaching could provide valuable insights into the most effective methods. Diligence implications suggest potential partnerships or investments in behavioral health solutions, particularly those that leverage community support and professional guidance.

Matched by conditions: Obesity

Adaptations métaboliques, énergétiques et Nutritionnelles à la Perte de Poids Chez l'Adolescent Avec obésité : rôle du degré de Perte de Poids. Etude POWELL-2

The POWELL-2 study, sponsored by the University Hospital of Clermont-Ferrand, aims to address the critical challenge of maintaining weight loss in adolescents with obesity. Given the rising prevalence of pediatric obesity, this research is timely and could lead to significant advancements in treatment protocols. The multidisciplinary approach combining behavioral, nutritional, and psychological interventions positions this study favorably in the market, potentially influencing future obesity management strategies. The insights gained may also open avenues for partnerships with pharmaceutical companies interested in obesity therapeutics, particularly those focusing on metabolic modulation. However, the competitive landscape includes various behavioral and pharmacological interventions already in development, necessitating thorough diligence to assess differentiation and potential market entry strategies.

Retrospective Evaluation of Sibutramine-Topiramate Therapy for Obesity in Real-World Outpatient Practice

The study sponsored by Falquetomed aims to evaluate the effectiveness and safety of the combination therapy of sibutramine and topiramate for obesity management in a real-world outpatient setting in Brazil. Given the rising prevalence of obesity and associated metabolic comorbidities, this study addresses a significant market need for affordable obesity treatments, particularly in low- and middle-income populations where newer therapies are often inaccessible due to high costs. The findings could position Falquetomed favorably in the competitive landscape of obesity treatments, especially if the combination therapy demonstrates meaningful efficacy and safety. The study's retrospective nature may limit the robustness of the data compared to prospective trials, but it could still provide valuable insights for clinical practice and inform future product development strategies.

Matched by conditions: Obesity & Overweight

The Effect of Frequency and Duration of Breaks in Sitting Time on Metabolic Cardiovascular Risk Factors

The study, sponsored by Rigshospitalet, Denmark, focuses on the impact of breaking prolonged sitting on metabolic cardiovascular risk factors in overweight males. Given the increasing prevalence of sedentary lifestyles and associated metabolic diseases, this research could inform public health initiatives and interventions aimed at reducing cardiovascular risks. The findings may also have implications for the development of lifestyle modification programs and products targeting sedentary populations. However, the competitive landscape includes various lifestyle and behavioral interventions, necessitating a thorough market analysis to identify unique selling propositions and potential partnerships.

Matched by conditions: Overweight and Obesity

Exercise and Pioglitazone for HIV-Metabolic Syndromes

The clinical trial investigated the combined effects of pioglitazone, a PPAR-gamma agonist, and structured exercise training on metabolic syndromes in HIV-infected individuals. Given the rising prevalence of metabolic disorders among HIV patients, this study addresses a significant unmet medical need. The findings could enhance pioglitazone's market positioning against other diabetes and metabolic syndrome treatments, particularly in the context of HIV-associated complications. The results may also support the development of combination therapies, potentially leading to new indications for pioglitazone and exercise interventions in this patient population.

Matched by conditions: Obesity

Semaglutide for the Reduction of Arrhythmia Burden in Overweight and Obese Patients With Atrial Fibrillation (Pilot Study)

The pilot study of semaglutide for reducing arrhythmia burden in overweight and obese patients with atrial fibrillation (AF) aims to explore a novel application of an established GLP-1 receptor agonist. Given the increasing prevalence of obesity and AF, successful outcomes could position semaglutide as a dual therapeutic option, enhancing its market potential beyond diabetes and weight management. However, the study has been withdrawn due to lack of funding, which raises concerns about the feasibility of advancing this indication without significant investment. Competitive analysis indicates that while semaglutide is well-positioned in the obesity and diabetes markets, the AF indication may face challenges from existing antiarrhythmic therapies and emerging treatments targeting similar patient populations.

Matched by conditions: Overweight and Obesity

Recruiting and Retaining Young Adults in Behavioral Weight Loss Treatment

The study, sponsored by Virginia Commonwealth University, aims to identify effective behavioral weight loss treatment formats for young adults, a demographic increasingly affected by obesity. With a growing market for weight management solutions, particularly among younger populations, the findings could inform future product development and marketing strategies. The competitive landscape includes various digital health platforms and traditional weight loss programs. The insights gained from this pilot study may enhance engagement and retention strategies, providing a competitive edge in a crowded market. Diligence implications include assessing the scalability of the intervention formats and potential partnerships with health organizations or tech companies focused on obesity management.

Matched by conditions: Obesity

A Site-Randomized Controlled Trial for Health Promotion in Girl Scouts: Healthier Troops in a SNAP

The 'Healthier Troops in a SNAP' trial, sponsored by Kansas State University, aims to address obesity prevention among young girls through a structured intervention in Girl Scouts troops. This initiative targets a demographic with increasing obesity rates, presenting a significant market opportunity for health promotion programs. The competitive landscape includes various obesity prevention initiatives, particularly those targeting children and adolescents. The successful implementation and outcomes of this program could lead to partnerships with health organizations and potential funding from public health initiatives. Diligence should focus on the scalability of the intervention and the potential for integration into broader health promotion strategies.

Matched by conditions: Obesity

Acting Flexible, Acting Resistant: the Upsides of an ACT Choice. A Randomized Comparison of Acceptance and Commitment Therapy Group Intervention and Cognitive Behavioral Therapy Group for the Treatment of Obese Patients

The study, sponsored by Istituto Auxologico Italiano, compares the efficacy of ACT and CBT in treating obesity, a significant public health concern affecting millions globally. With obesity treatment markets projected to grow, the findings could position ACT as a viable alternative or complement to traditional CBT, potentially expanding treatment options in behavioral health. The results may influence clinical practice guidelines and reimbursement policies, enhancing market access for ACT-based interventions. Given the increasing recognition of mental health's role in obesity management, this study could attract interest from pharmaceutical companies and health technology firms looking to innovate in this space.

Matched by conditions: Obesity

Pupillographie Als Screeningtest für Cerebrale Insulinresistenz

The study conducted by the University Hospital Tuebingen aims to explore the potential of pupillography as a noninvasive screening tool for cerebral insulin resistance, which is relevant in the context of obesity and metabolic disorders. Given the increasing prevalence of obesity and associated metabolic diseases, this research could pave the way for novel diagnostic approaches in managing these conditions. The findings may attract interest from pharmaceutical companies focusing on metabolic disorders, particularly those developing insulin-related therapies. However, the absence of FDA regulation for the drug and device used in this study may limit immediate commercial applications. Further validation and potential partnerships will be essential for translating these findings into clinical practice.

Matched by conditions: Obesity

Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women

The clinical trial, sponsored by the University of Sao Paulo, investigates the effects of the levonorgestrel-releasing intrauterine device (IUS-LNG) on arterial function and hemostatic parameters in obese women, particularly those with polycystic ovary syndrome (PCOS). Given the rising prevalence of obesity and associated cardiovascular risks, this study addresses a significant unmet need in contraceptive options for this demographic. The findings could enhance the market positioning of IUS-LNG as a safer contraceptive alternative for obese women, potentially leading to increased adoption in clinical practice. Competitive implications include the need for differentiation from other contraceptive methods, particularly non-hormonal options like the Copper IUD, which serves as the comparator in this trial. Diligence considerations should focus on the long-term safety and efficacy data, particularly concerning cardiovascular health outcomes.

Metabolic Effects of Duodenal Jejunal Bypass Liner for the Treatment of Adipose Patients With Type 2 Diabetes Mellitus

The DJBL represents a novel, reversible intervention for managing obesity and T2DM, addressing a significant unmet need in the market for patients who have not succeeded with traditional weight loss methods. Given the rising prevalence of obesity and diabetes globally, this device could capture a substantial share of the weight loss and diabetes management market. The competitive landscape includes traditional bariatric surgeries and pharmacological interventions, but DJBL's non-invasive nature may offer a distinct advantage. Diligence considerations should focus on long-term efficacy, safety data, and potential regulatory pathways for commercialization.

Matched by conditions: Obesity

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

VK2735, a dual agonist targeting GLP-1 and GIP receptors, is being evaluated for weight management in obese and overweight adults with comorbid conditions. The obesity treatment market is rapidly expanding, driven by increasing prevalence rates and demand for effective therapies. VK2735's unique mechanism may provide a competitive edge over existing GLP-1 receptor agonists, particularly if it demonstrates superior efficacy and safety profiles. Viking Therapeutics, Inc. should prepare for potential partnerships or licensing opportunities based on trial outcomes, as well as consider strategies for market entry and positioning against established players in the obesity treatment landscape.

Matched by conditions: Weight Loss

In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database

In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database is a registry-stage clinical asset sponsored by Novo Nordisk A/S in Obesity, Overweight. SEO and diligence focus: Liraglutide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Obesity

Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery

This study investigates the effects of gut hormones, specifically GLP-1 and DPP-4 inhibition, on food intake and glucose metabolism post-Roux-en-Y gastric bypass (RYGB). Given the rising prevalence of obesity and related metabolic disorders, successful outcomes could enhance the commercial viability of GLP-1 receptor antagonists and DPP-4 inhibitors in obesity management. The competitive landscape includes established players like Merck (sitagliptin) and Novo Nordisk (liraglutide), necessitating a thorough diligence process to assess market entry strategies and potential partnerships. The findings may also inform future product development and positioning in the obesity treatment market.

Matched by conditions: Severe Obesity

Behavioral Weight Loss Intervention Utilizing Mobile Health Technology in Hematopoietic Stem Cell Transplant Patients (BWL001)

The BWL001 trial, sponsored by the Jonsson Comprehensive Cancer Center, targets a niche yet critical market segment of adolescents and young adults who are obese following hematopoietic stem cell transplantation (HSCT). This population is often overlooked in weight management interventions, presenting a unique opportunity for the development of tailored behavioral health solutions. The integration of mobile health technology and coaching may enhance patient engagement and adherence, potentially leading to improved health outcomes. Given the rising prevalence of obesity in post-transplant patients, successful outcomes could position the intervention as a standard care approach, influencing market dynamics and attracting interest from healthcare providers and payers. Competitive landscape analysis should focus on existing obesity management solutions and mobile health applications, assessing their efficacy and market penetration.

Efficacy of a Novel Digital Platform to Scale-Up a Personalized Prenatal Weight Gain Intervention Using Control Systems Methodology

The HMZ 2.0 intervention, sponsored by Penn State University, aims to address the growing concern of gestational weight gain (GWG) among pregnant women with overweight and obesity. With an estimated 144 participants, the trial seeks to validate a digital platform that personalizes weight management strategies, potentially leading to improved maternal and infant health outcomes. The intervention's focus on behavioral modification through technology positions it favorably in the expanding digital health market, particularly in maternal health. As the prevalence of obesity during pregnancy rises, successful outcomes could enhance market penetration and attract partnerships with healthcare providers and payers. The competitive landscape includes traditional prenatal care and emerging digital health solutions, necessitating a robust demonstration of efficacy and usability to differentiate from existing offerings.

Matched by conditions: Overweight and Obesity

Effectiveness of an Agentic AI-Based Personalized Dietary Management Algorithm in Health Screening Participants: A Randomized Controlled Trial

The trial, sponsored by Seoul National University Hospital, aims to evaluate the effectiveness of an AI-driven dietary management system in improving dietary behaviors and metabolic health among adults undergoing health screening. This innovative approach positions the asset within the growing digital health and personalized nutrition markets, which are projected to expand significantly due to increasing health awareness and the demand for tailored health solutions. The competitive landscape includes traditional dietary management programs and emerging digital health platforms. Successful outcomes could enhance the sponsor's reputation in the digital health space and attract potential partnerships or investments. However, the trial's not-yet-recruiting status indicates a need for ongoing diligence regarding recruitment timelines and regulatory considerations.

Matched by conditions: Dietary Behavior; Metabolic Health; Obesity; Lifestyle Modification; Metabolic Syndrome Risk

Testing a Behavioral Weight Loss Intervention for Emerging Adults Implemented Within College Health Service Centers

This pilot randomized controlled trial, sponsored by The Miriam Hospital, aims to assess the acceptability and effectiveness of a behavioral weight loss intervention specifically designed for emerging adults (ages 18-25) with overweight or obesity. Given that approximately 40% of this demographic is affected by weight issues and is underrepresented in traditional weight loss programs, the study addresses a significant market need. If successful, the intervention could be integrated into college health service centers, potentially leading to widespread adoption across educational institutions. The findings may also inform future larger-scale studies and commercial applications in behavioral health interventions targeting obesity, presenting opportunities for partnerships with educational institutions and health organizations.

Matched by conditions: Obesity and Overweight

Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS003)

The CBS003 trial, sponsored by the University of Virginia, aimed to evaluate the effects of short-term hydrocortisone on androgen overproduction in overweight girls with hyperandrogenemia. The study was withdrawn prior to enrollment, indicating potential challenges in feasibility or strategic alignment. The market for treatments addressing hyperandrogenemia, particularly in the context of obesity and conditions like Polycystic Ovary Syndrome (PCOS), remains significant, with a growing demand for effective interventions. Competitors in this space may include hormonal therapies and lifestyle interventions, but the withdrawal of this trial may raise concerns regarding the viability of hydrocortisone as a treatment option. Further diligence is warranted to assess ongoing research and alternative therapeutic approaches.

Matched by conditions: Obesity

Predicting Difficult Intubation in Obese Patients: The Role of Anthropometric Measurements and Ultrasonograpic Suprasternal Adipose Tissue Thickness

The study conducted by Ankara City Hospital Bilkent addresses a critical need in the anesthesiology field, particularly concerning the management of obese patients undergoing elective abdominal surgery. With obesity rates rising globally, the ability to predict difficult intubation could significantly reduce complications and improve surgical outcomes. The findings may lead to the development of new guidelines or tools for anesthesiologists, potentially creating a market for devices or software that utilize these predictive measurements. Competitors in the field may include companies focused on surgical and anesthetic devices, as well as those developing AI-driven predictive analytics for patient management. Diligence should focus on the integration of these findings into clinical practice and the potential for patenting any novel methodologies or devices that arise from this research.

An Open-Label Study of Mibavademab (REGN4461), a Leptin Receptor Agonist, for the Treatment of Monogenic Obesity Due to Biallelic Loss of Function Variants of the LEP Gene

Regeneron Pharmaceuticals is advancing mibavademab (REGN4461) as a potential treatment for monogenic obesity linked to LEP gene mutations. This niche indication addresses a specific patient population with unmet medical needs, potentially allowing for premium pricing due to the rarity of the condition. The obesity treatment market is competitive, with several established therapies; however, mibavademab's unique mechanism may differentiate it. The trial's success could position Regeneron favorably in the obesity treatment landscape, particularly as obesity continues to gain attention as a public health issue. Diligence should focus on the trial's enrollment pace and safety profile, as well as potential regulatory hurdles.

Matched by conditions: Monogenic Obesity

Impact of an Effort Rehabilitation Program for Overweight or Obese Children and Teens on Quality of Life and Wellbeing: A French Monocentric Prospective Study

The study, sponsored by Groupe Hospitalier de la Region de Mulhouse et Sud Alsace, evaluates an effort rehabilitation program for overweight and obese children and teens, addressing a significant public health issue in pediatric obesity. Given the rising prevalence of obesity among youth, particularly in developed nations, this program could position the sponsor as a leader in pediatric obesity management. The findings may support the development of similar programs or interventions, potentially attracting partnerships or funding from health organizations and government bodies focused on obesity prevention and management. The results could also inform future therapeutic strategies and health policies aimed at improving quality of life and physical activity levels in this demographic.

Matched by conditions: Pediatric Obesity

Understanding Mechanisms of Health Behavior Change

The study conducted by the University of Colorado, Boulder, explores the impact of incentive structures on health behavior engagement, particularly in the context of dietary modifications for overweight and obese individuals. Given the rising prevalence of obesity and related health conditions, the findings could have significant implications for public health initiatives and commercial programs aimed at improving dietary habits. The insights gained may inform the development of incentive-based health interventions, potentially positioning the sponsor or collaborators as leaders in behavioral health strategies. Competitive implications include the potential for partnerships with health technology companies or wellness programs that seek to leverage behavioral economics in their offerings.

Matched by conditions: Overweight and Obesity

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight

VK2735, developed by Viking Therapeutics, is positioned to address the significant market for weight management in patients with Type 2 Diabetes Mellitus (T2DM), particularly among those who are obese or overweight. The obesity treatment market is expanding rapidly, driven by increasing prevalence rates and a growing focus on metabolic health. VK2735's dual mechanism of action may provide a competitive edge over existing therapies, particularly GLP-1 receptor agonists, by potentially enhancing weight loss efficacy and improving glycemic control. The trial's design, being a multicenter, randomized, double-blind, placebo-controlled study, aligns with regulatory expectations and may facilitate a smoother path to market approval. However, the exclusion of certain diabetes treatments may limit the patient population and affect recruitment timelines. The anticipated primary completion date in July 2027 suggests a potential market entry in late 2028 or early 2029, contingent upon successful trial outcomes.

"HIIT Med Kiloene" Investigating the Physical, Metabolic, and Psychosocial Effects of High-intensity Interval Training (HIIT) in Childhood Obesity

The 'HIIT Med Kiloene' study, sponsored by Aalborg University Hospital, addresses a significant public health issue in Denmark, where childhood obesity affects 15% of children. The study aims to establish the efficacy of HIIT combined with lifestyle interventions in improving metabolic and psychosocial health in obese children and adolescents. Given the increasing prevalence of childhood obesity and its associated health complications, successful outcomes could lead to the development of community-based obesity management programs, potentially creating a new market for lifestyle intervention strategies. The collaboration with local municipalities and healthcare institutions enhances the feasibility of implementation and may attract funding or partnerships from health organizations and public health initiatives. The results could position the sponsoring institutions as leaders in innovative obesity treatment methodologies, influencing future guidelines and practices in pediatric obesity management.

Northern Lights Physical Activity Program for Management of Type 2 Diabetes Early in Life: Aboriginal Youth Mentorship Program

The Northern Lights Physical Activity Program, sponsored by the University of Manitoba, targets Type 2 diabetes prevention among Aboriginal youth through a peer-led mentorship model. This program is particularly relevant given the rising prevalence of obesity and diabetes in Indigenous populations. The intervention leverages community engagement and culturally relevant practices, which may enhance its acceptance and effectiveness. The findings could inform future public health initiatives and interventions aimed at similar demographics, potentially leading to partnerships with governmental and non-governmental organizations focused on youth health. The completion of this trial may also attract interest from pharmaceutical companies and health organizations looking to invest in preventative health strategies, particularly those that address social determinants of health.

Matched by conditions: Obesity

Trading Sugar for Sparkles in Adolescents, A Sensory Approach for Reducing Added Sugar From Sweetened Beverages

The clinical trial titled 'Trading Sugar for Sparkles in Adolescents' aims to address the high prevalence of obesity and excessive sugar consumption among Black/African American and Latine adolescents. This demographic is at a heightened risk for obesity-related health issues, making the trial's focus particularly relevant. The potential market for healthier beverage alternatives is significant, especially as consumer awareness of health and wellness continues to rise. If successful, the findings could lead to new dietary recommendations and interventions, positioning the sponsoring institutions as leaders in adolescent health research. The competitive landscape includes existing beverage companies and health organizations focusing on sugar reduction strategies, necessitating a thorough analysis of market entry and partnership opportunities.

Matched by conditions: Obesity, Adolescent

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome.

The clinical trial conducted by Novo Nordisk A/S investigates the efficacy of liraglutide for weight management in pediatric patients with Prader-Willi Syndrome (PWS). Given the unique challenges associated with obesity in this population, successful outcomes could position liraglutide as a leading therapeutic option in a niche market. The global obesity treatment market is expanding, with increasing prevalence rates among children and adolescents. Competitive analysis indicates that while there are existing obesity treatments, liraglutide's specific application in PWS may provide a unique selling proposition. Diligence should focus on regulatory pathways, potential market access challenges, and reimbursement strategies, particularly given the specialized nature of the patient population.

Matched by conditions: Obesity

Real-world Effectiveness and Dosing Patterns of Tirzepatide: A Multicentre Retrospective Observational Study in the Netherlands

Tirzepatide, marketed under the name Mounjaro, is positioned as a novel therapeutic option for obesity management, demonstrating significant weight loss in clinical trials (up to 21%). This multicenter retrospective observational study in the Netherlands aims to evaluate real-world effectiveness and dosing patterns, which could provide critical insights into its practical application and market acceptance. The study's findings may influence prescribing habits and reimbursement strategies, especially as obesity treatment continues to gain attention in healthcare systems. Given the increasing prevalence of obesity and associated comorbidities, Tirzepatide has the potential to capture a substantial share of the obesity treatment market, particularly if it demonstrates favorable outcomes in real-world settings compared to existing therapies.

Matched by conditions: Overweight , Obesity

A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

Guanfacine Extended Release (GXR) is being evaluated for its efficacy in reducing aggression and self-injurious behavior in individuals with Prader-Willi Syndrome (PWS). This clinical trial, sponsored by Maimonides Medical Center, addresses a significant unmet need in the management of behavioral symptoms associated with PWS, a genetic disorder affecting appetite and behavior. If successful, GXR could capture a niche market within the pediatric and adolescent populations suffering from PWS, potentially expanding its use beyond its current FDA-approved indications for hypertension and ADHD. The competitive landscape includes other behavioral interventions and pharmacotherapies, but GXR's specific targeting of aggression and self-injury in PWS may provide a unique selling proposition. Diligence should focus on the trial's safety profile and metabolic effects, as these will be critical for market acceptance and physician adoption.

Effect of Potato Fiber on Appetite and Fecal Fat Excretion

The study conducted by the University of Copenhagen explores the potential of potato-derived fibers in appetite suppression and fecal fat excretion, which may have implications for obesity management and weight control. The findings could position these dietary fibers as novel ingredients in functional foods and dietary supplements aimed at weight management. Given the increasing global focus on obesity and metabolic health, this research may attract interest from food manufacturers and nutraceutical companies. Competitive analysis should consider existing dietary fiber products and their efficacy in similar applications, as well as regulatory considerations for health claims associated with these fibers. Diligence should focus on the commercial viability of the FiberBind and RG-I fibers, including potential partnerships or licensing opportunities.

Matched by conditions: Obesity

Evaluation the Effect of Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Type 2 Diabetic Iraqi Patients

The trial evaluates the adjunctive use of Mangosteen with established diabetes medications (Sitagliptin and Metformin) in a specific population (Iraqi patients with newly diagnosed T2DM). If successful, this could position Mangosteen as a complementary therapy in the diabetes market, which is experiencing significant growth due to rising prevalence rates. The competitive landscape includes other adjunct therapies and natural supplements, necessitating a thorough market analysis and potential partnerships for commercialization. Diligence should focus on the safety profile and efficacy data to assess market entry viability.

Matched by conditions: Obesity Type 2 Diabetes Mellitus

Effect of Replacing HFCS With Sucromalt on Glucose Tolerance, Blood Lipids and Inflammatory Markers in Subjects With Raised Waist Circumference

The clinical trial conducted by the University of Toronto investigates the potential of sucromalt as a healthier alternative to HFCS in sweetened beverages, targeting the growing market of health-conscious consumers and individuals with metabolic syndrome. With rising obesity rates and associated health risks, sucromalt could position itself as a viable product in the functional food and beverage sector. The findings may provide a competitive edge against traditional sweeteners, particularly in markets focused on diabetes management and cardiovascular health. Companies may need to assess the regulatory landscape and potential partnerships for commercialization, as well as consider the implications of consumer trends towards lower glycemic index products.

Matched by conditions: Abdominal Obesity

A Randomized, Double-blind, Placebo-controlled Study of Akkermansia Muciniphila AKK PROBIO in Improving Obesity and Metabolic Abnormalities in Children and Adolescents Aged 7-18 Years

The clinical trial, sponsored by Central South University, aims to evaluate the efficacy and safety of Akkermansia muciniphila (AKK PROBIO) in addressing obesity and metabolic abnormalities in children and adolescents aged 7 to 18 years. Given the rising prevalence of obesity in pediatric populations, this study targets a significant market opportunity in pediatric obesity management. If successful, AKK PROBIO could position itself as a novel therapeutic option in the growing probiotics market, which is increasingly focusing on metabolic health. The competitive landscape includes other probiotics and lifestyle interventions, but AKK's unique mechanism of action may provide a differentiated offering. Diligence should focus on regulatory pathways, potential partnerships for commercialization, and reimbursement strategies in pediatric healthcare.

Matched by conditions: Obesity

Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD)

The TINSAL-CVD trial, sponsored by Joslin Diabetes Center, investigates the efficacy of salsalate in reducing coronary artery plaque volume in patients with established cardiovascular disease. Given the rising prevalence of cardiovascular diseases and the increasing focus on anti-inflammatory therapies, this study positions salsalate as a potential therapeutic option in a competitive landscape dominated by statins and other cardiovascular agents. The results could enhance market positioning for salsalate, especially if significant clinical benefits are demonstrated, potentially leading to expanded indications and increased market share in cardiovascular therapeutics. Diligence should focus on the safety profile and any adverse events reported during the trial, as well as the regulatory pathway for approval.

Matched by conditions: Overweight

Enhancing Effectiveness Of Existing Weight Management Programs For Teens With Severe Obesity: A 6-Month Feasibility Pilot

The POWER pilot study, sponsored by Children's Hospital Medical Center, Cincinnati, evaluated the effectiveness of enhanced weight management programs for adolescents with severe obesity. The study's unique approach, particularly the inclusion of a tailored orientation session for families, may provide a competitive edge in the pediatric obesity treatment market. Given the rising prevalence of obesity among youth, this program could attract significant interest from healthcare providers and payers. The findings may support the development of scalable interventions that can be integrated into existing healthcare systems, potentially leading to partnerships or licensing opportunities. The results could also inform future product development in the obesity management sector.

Matched by conditions: Obesity

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VCT220 Tablets in Overweight or Obese Participants

VCT220, a small molecule GLP-1 receptor agonist, is currently undergoing a Phase 3 clinical trial aimed at evaluating its efficacy and safety in overweight or obese adults. The obesity treatment market is rapidly expanding, driven by increasing prevalence rates and a growing focus on weight management solutions. VCT220's unique profile may position it competitively against existing GLP-1 therapies such as semaglutide and liraglutide. The trial's design, which includes a placebo-controlled approach and a robust participant enrollment of 840, suggests a significant investment in demonstrating clinical efficacy. Successful outcomes could lead to a strong market entry, particularly in regions with high obesity rates, such as China, where the trial is being conducted. However, the competitive landscape is intense, and Vincentage Pharma must navigate potential regulatory hurdles and market access challenges.

Matched by conditions: Obesity

Diabetes Prevention Program Feasibility Study of Breastfeeding - Electronic Monitoring of Mom's Schedule 2.0

The Diabetes Prevention Program Feasibility Study of Breastfeeding - eMOMS 2.0, sponsored by the University of Kansas Medical Center, aims to address postpartum weight retention and lactation duration among overweight or obese women. This study leverages a mobile health application to deliver a comprehensive intervention combining breastfeeding support with a diabetes prevention program. Given the increasing prevalence of obesity and diabetes, particularly in postpartum women, this study targets a significant market segment. The findings could inform future interventions and health policies, potentially leading to partnerships with healthcare providers and mHealth companies. Competitive implications include the growing interest in digital health solutions and maternal health programs, indicating a need for diligence in assessing existing and emerging competitors in this space.

The Effect of a Stepped-care Approach to Long-term Weight Loss

The study, sponsored by the University of Pittsburgh, evaluated the effectiveness of a 'stepped-care' approach versus a standard behavioral weight loss program for overweight and obese adults. Given the rising obesity rates in the U.S., this research addresses a significant public health concern. The stepped-care model may offer a competitive advantage in the weight loss program market by potentially improving long-term outcomes and participant engagement. Companies in the obesity management sector should consider the implications of these findings for developing scalable, effective weight loss solutions. The cost-effectiveness evaluation may also attract interest from payers and health systems looking to reduce obesity-related healthcare costs.

Matched by conditions: Obesity

The Effects of a Low Energy Diet Versus Low Energy Diet and Intragastric Balloon in Adults With Obesity, All in Combination With Group Treatment: a Randomized, Controlled Trial

This clinical trial, sponsored by Region Örebro County, aims to evaluate the efficacy of a combined treatment approach for obesity, which includes a low energy diet, cognitive behavioral therapy, and the use of an intragastric balloon. Given the rising prevalence of obesity and its associated health risks, successful outcomes could position this treatment as a competitive option in the obesity management market. The trial's findings may lead to improved quality of life for patients and reduced healthcare costs, making it attractive for healthcare providers and payers. The potential for significant weight loss and maintenance could also enhance marketability in a landscape increasingly focused on holistic and sustainable weight management solutions.

Matched by conditions: Obesity

A Randomized Controlled, Open-label, Multi-center Study With 16-week Beinaglutide or Dulaglutide Assessing Effects on Glucose Control and Weight Loss in Type 2 Diabetes With Overweight or Obesity.

The clinical trial is evaluating Beinaglutide, a novel GLP-1 receptor agonist, against Dulaglutide, an established competitor in the treatment of Type 2 diabetes in overweight or obese patients. Given the rising prevalence of diabetes and obesity, particularly in China, this trial addresses a significant market need. If successful, Beinaglutide could capture market share from Dulaglutide, which is already well-established. The trial's multi-center design and recruitment of 120 participants across four sites enhance its credibility and potential for robust data. The outcomes may influence prescribing practices and market dynamics in the GLP-1 agonist segment, which is experiencing increasing competition. Companies should monitor the trial's progress closely for potential partnership or acquisition opportunities.

Matched by conditions: Overweight or Obesity

Translating Insights From Behavioral Economics and Self-Determination Theory to Promote Sustained Weight Loss Among Obese Employees

The study, sponsored by the University of Michigan, explores the effectiveness of financial incentives and personalized messaging in promoting sustained weight loss among obese employees. Given the increasing prevalence of obesity and the associated healthcare costs, successful interventions in this area could have significant market potential. The competitive landscape includes various behavioral weight loss programs and digital health solutions. Companies focusing on obesity management may consider the findings to enhance their offerings or develop new incentive-based programs. Diligence implications suggest a need for further exploration of scalability and integration into existing workplace wellness programs.

Matched by conditions: Weight Loss

Testing the Gravitostat in Humans: the Impact of a Weighted Vest in Patients Post Bariatric Surgery on Fat-free Mass Retention and Weight Loss

The trial, sponsored by University College Dublin, aims to explore the impact of a weighted vest on fat-free mass retention and weight loss in patients post-bariatric surgery. Given the rising prevalence of obesity and the increasing number of bariatric surgeries performed globally, successful outcomes from this study could position the findings as a novel adjunctive therapy in weight management. The market for obesity treatments is substantial, with a growing demand for effective post-operative care solutions. However, the trial's suspension due to funding issues raises concerns regarding its viability and the potential for future commercialization. Competitors in the obesity management space may include pharmaceutical interventions and other non-invasive devices, necessitating a thorough competitive analysis.

Matched by conditions: Obesity

The Impact of Low Intensity Physical Activity During Sitting on Glycemic Control and Vascular Function in Obese Individuals

The study conducted by the University of Missouri-Columbia investigates the potential of low intensity physical activity to mitigate the adverse effects of prolonged sitting, particularly in obese individuals with metabolic syndrome. Given the rising prevalence of obesity and associated metabolic disorders, this research addresses a significant public health concern. If successful, the findings could lead to the development of behavioral interventions or lifestyle modification programs aimed at improving vascular health and glycemic control, potentially creating a niche market in preventive health strategies. Competitive implications include positioning against existing cardiovascular and metabolic health interventions, emphasizing a non-pharmacological approach. Diligence considerations should focus on the scalability of the intervention and potential partnerships with health organizations or fitness industries.

Combined Eating Disorder and Weight Loss Online Guided-Self Help Intervention Pilot Study

The pilot study conducted by Washington University School of Medicine addresses a significant gap in the treatment of comorbid eating disorders (EDs) and obesity among young adults, particularly college students. The combined intervention leverages online, guided self-help methodologies, which are increasingly relevant in the digital health landscape. Given the rising prevalence of EDs and obesity, this program could tap into a substantial market, particularly among the college demographic. The competitive landscape includes traditional therapy and other digital health solutions, but few directly address the intersection of EDs and weight management. Successful outcomes could position this intervention as a leading solution in a niche market, potentially attracting interest from healthcare providers and insurers focused on preventive care and mental health integration.

Matched by conditions: Obesity

Immunomodulatory Role of Eosinophils in Determining Inflammation and Insulin Sensitivity in Human Adipose Tissue- Aims 1&2

The study conducted by Mayo Clinic investigates the immunomodulatory role of eosinophils in adipose tissue, particularly focusing on their relationship with inflammation and insulin sensitivity. Given the rising prevalence of obesity and insulin resistance globally, this research could have significant implications for developing therapeutic strategies targeting eosinophils to improve metabolic health. The findings may enhance the understanding of obesity-related inflammation and lead to potential dietary supplement interventions, such as fish oil, which could be marketed to consumers seeking to manage weight and metabolic health. The competitive landscape includes other obesity and insulin resistance therapies, but the unique focus on eosinophils may provide a novel angle for differentiation. Diligence should assess the potential for commercialization based on the study's outcomes and the regulatory pathway for any resultant products.

Matched by conditions: Obesity

Network-based Epigenome-Wide associaTion Study in Obesity precisioN Medicine: NEWTON Clinical Trial

The NEWTON Clinical Trial, sponsored by the University of Campania Luigi Vanvitelli, aims to explore the epigenetic underpinnings of obesity and its complications through Next Generation Sequencing (NGS). Given the rising global obesity epidemic, which affects over 650 million individuals, this study addresses a significant unmet medical need. The identification of subgroups of obesity patients who may respond differently to treatments could enhance personalized medicine approaches, potentially leading to the development of targeted therapies. The findings may provide valuable insights for pharmaceutical companies focusing on obesity and metabolic disorders, as well as for those developing diagnostic tools based on epigenetic biomarkers. The competitive landscape includes other obesity-related studies, but the unique focus on epigenetics and network-based algorithms may differentiate this trial. Diligence should consider the regulatory landscape for epigenetic therapies and the potential for partnerships with biotech firms specializing in genomics and personalized medicine.

Differential Effects of Oral and Intravenous Lipid Administration on Leptin Signaling

The study investigates the differential effects of oral versus intravenous lipid administration on leptin signaling in obese individuals, a population with significant unmet medical needs due to leptin resistance. The findings could have implications for developing new therapeutic strategies targeting obesity and metabolic disorders, potentially positioning the sponsor, Beth Israel Deaconess Medical Center, as a leader in this niche market. Given the rising prevalence of obesity and related metabolic diseases, successful outcomes could attract interest from pharmaceutical companies looking to expand their portfolios in obesity management. Competitive analysis should focus on existing therapies targeting leptin pathways and metabolic regulation, as well as emerging technologies in lipid metabolism modulation.

Matched by conditions: Obesity

Does Enhanced Protein Intake Preserve Function and Lean Muscle Mass During Weight Reduction in Frail, Obese Older Adults?

The MEASUR-UP trial, sponsored by Duke University, investigates the impact of enhanced protein intake on preserving muscle mass during weight loss in frail, obese older adults. Given the growing aging population and rising obesity rates, this study addresses a significant market need for effective weight management strategies in this demographic. The findings could lead to new dietary recommendations or products targeting protein supplementation, particularly from animal sources, which may appeal to both healthcare providers and consumers. Competitive implications include potential partnerships with nutritional supplement companies and the meat industry, particularly beef producers, as the study emphasizes high-quality protein sources. Diligence should focus on the scalability of dietary interventions and the regulatory landscape surrounding dietary supplements.

Matched by conditions: Weight Loss

Using Patient Navigators to Facilitate Weight Management Among Adults

The trial, sponsored by M.D. Anderson Cancer Center, investigates the role of patient navigators in enhancing enrollment and participation in weight management programs among obese adults. Given the rising prevalence of obesity and its associated health risks, successful outcomes could position the navigators as a valuable resource in public health initiatives and weight management services. The findings may lead to partnerships with healthcare providers and weight management program developers, potentially opening new revenue streams in the health coaching and wellness sectors. The competitive landscape includes traditional weight loss programs and emerging digital health solutions, necessitating a thorough market analysis to identify strategic positioning and differentiation. Diligence should focus on scalability and integration with existing healthcare frameworks.

Matched by conditions: Obesity

Imagine HEALTH (Healthy Eating Active Living Total Health) Study: Guided Imagery Lifestyle Intervention to Promote Health and Prevent Diabetes in Youth

The Imagine HEALTH study addresses the critical public health issue of childhood obesity, particularly among Latino adolescents, by utilizing a mind-body intervention approach. The market for obesity prevention and management is substantial, with increasing focus on non-pharmacological interventions. This study's findings could position the University of Southern California as a leader in innovative lifestyle interventions, potentially attracting partnerships with public health organizations and educational institutions. The competitive landscape includes traditional weight-loss programs and emerging behavioral health interventions, necessitating a clear differentiation based on the psychosocial approach and community engagement. Diligence should focus on scalability, potential for integration into school curricula, and alignment with public health initiatives aimed at reducing childhood obesity rates.

A Multicenter, Multiple-dose Escalation, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Ecnoglutide, an oral formulation targeting GLP-1 receptors, is positioned to address the growing obesity epidemic in China, where the prevalence of overweight and obesity is rising. The study's multicenter, randomized design enhances its credibility and potential for regulatory approval. Given the competitive landscape, including established GLP-1 receptor agonists like semaglutide and liraglutide, ecnoglutide's oral delivery may provide a significant differentiation point. The trial's focus on safety and pharmacokinetics will be critical for market acceptance and could influence pricing strategies. The estimated enrollment of 84 participants indicates a moderate scale for initial safety assessments, which may expedite subsequent phases if results are favorable.

Matched by conditions: Overweight and/or Obesity

Análisis de Medidas bioparamétricas Para Correlacionar Los hábitos Diarios y Reducir la tensión Arterial

The study, sponsored by the University of Alicante, investigates the impact of a mobile application combined with Mediterranean diet recommendations on cardiovascular health in adults over 40 with slightly elevated blood pressure. Given the rising prevalence of hypertension and related cardiovascular diseases in Spain, this intervention addresses a significant public health concern. The use of machine learning in the application may provide a competitive edge in the digital health market, particularly in preventive healthcare solutions. The findings could support the development of similar applications targeting lifestyle modifications, potentially leading to partnerships with health organizations or commercial entities focused on chronic disease management.

Matched by conditions: Overweight and Obesity

School Meals in Denmark: Evaluation of a National School Meal Pilot Program on Children's Health, Learning and Well-being - a Natural Experiment

The study, sponsored by the University of Copenhagen, evaluates the impact of a national school meal program on children's health, well-being, and learning outcomes in Denmark. This initiative aligns with increasing global interest in public health interventions aimed at improving childhood nutrition and addressing obesity. The findings could have significant implications for policymakers and educational institutions, potentially influencing future funding and implementation of similar programs. The study's focus on cost-effectiveness may attract interest from public health organizations and foundations, such as The Novo Nordic Foundation, which are invested in improving children's health outcomes. The results may also inform the development of nutritional guidelines and interventions in other countries, creating a broader market for health-related educational programs and products.

Matched by conditions: Childhood Obesity